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Background: Occurrence of Cystic Fibrosis (CF) in more than one member in a family is not un-
common. The aim of our study was to assess the influence of multiple siblings with CF on dis-
ease expression and outcome.
Methods: Study group consisted of 2-siblings (2-sibs, nZ 42) or 3/4 siblings (3/4-sibs, nZ 22)
with CF in one family. Each sibling was matched by age, mutation, and gender to a single CF
patient.
Results: 3/4-sibs subgroup compared to singles showed a lower mean FEV1 with a faster
decline rate (58.4  27.5 vs. 72.7  25.4 and 5  6.4 vs. 1.7  2.8 %predicted decline/year
respectively, p < .05), more airway colonization by Pseudomonas aeruginosa and Mycobacte-
rium abscessus (15 (68%) vs. 8 (36%) and 7 (32%) vs. 4 (18%), respectively, p < .05) and more
lung transplants (5 (23%) vs. 2 (9%), respectively, p < .02). Last mean FEV1 within 3/4-sibs
was significantly lower for the youngest sib (p < .05).
Conclusions: Three or more CF patients in one family may be a risk factor for more severe dis-
ease and poor prognosis. In our view this reflects the burden of disease on the patients and
families.
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Cystic Fibrosis (CF) is an autosomal recessive disease
characterized by loss of function of CF Transmembrane
conductance Regulator (CFTR) protein, which results
mainly in respiratory, gastrointestinal, and fertility mani-
festations. In spite of widespread use of genetic testing and
newborn screening, the occurrence of CF in more than one
member in a family still exists in different populations. The
sick siblings differ in different aspects of disease expression
and progression. Age of diagnosis of the younger sibling is
often earlier due to awareness of family and caregivers
[1e3]; however, newly diagnosed CF through newborn
screening may promote the diagnosis of an undiagnosed
older sibling with CF [4]. The early diagnosis contributes to
better Pulmonary Function Tests (PFTs) later in life [3,5];
although similar clinical presentation of disease was shown
between siblings [1,3,5], there is contradicting data in re-
gard to disease progression and outcome [2,3,5]. Airway
colonization by the same strain of Pseudomonas aeruginosa
is often seen among siblings with CF [6], but it is unclear
whether younger siblings are colonized earlier in life as a
result of transmission from the older chronically colonized
sibling [1e3]. The burden of disease in CF is tremendous
[7,8] and has enormous impact on family choices of future
family planning [8], especially on the decision whether to
abort a second fetus with CF [9,10]. The aim of our study
was to assess the influence of multiple CF patients in a
single family on disease course and outcome.Methods
Subjects
Study population consisted of patients with proven CF by
clinical characteristics and identified CFTR alteration mu-
tation and/or pathological sweat chloride test (above
60 mmol/L). All the patients are part of the National CF
Center, Edmond and Lily Safra Children Hospital, Sheba
Medical Center, Israel. The inclusion criterion for the study
group was at least two siblings with CF in a family. Siblings
were defined as sharing both maternal and parental origin.
Inclusion criterion for the single group was CF patient
without siblings with CF. The single subjects were age,
gender, and class mutation matched to the study subjects
individually.Study design e a longitudinal cross-sectional
retrospective study
We retrospectively obtained patients’ data between 2001
and 2013 from records of the CF patients. The information
included anthropometric data, age, gender, mutations;
clinical parameters such as growth indices, CF-associated
diseases, airway bacterial colonization, Forced Expiratory
Flow in 1 s (FEV1), number of hospitalizations, organ
transplantation; and social evaluations.
The work was approved by the appropriate ethics com-
mittee of the institution in which it was performed.Analysis of data
Data was compared between the siblings groups and the
single group in order to assess differences in disease course
and outcome. Primary outcomes reflected disease pro-
gression and included PFTs, growth indices, number of
hospitalizations, and organ transplantation. Secondary
outcomes included CF-associated diseases such as pancre-
atic insufficiency (PI), CF-related diabetes (CFRD), and
airway bacterial colonization. The study group included 2-
subgroups e one with 2-siblings and the other with 3/4
siblings within a single family. Each subject within the
groups had their own matched single patient.
Statistical analysis
The main comparison was between the sibling and its
matched single. Accordingly paired t-tests were used to
establish significance. The number of children/group having
infection or related disease was analyzed separately by
Fisher exact tests. p < 0.05 was considered significant and
p Z 0.06 was considered as trend. We used the SPSS Soft-
ware statistical package.
Results
The sibs group included 64 patients: 21 pairs of 2-sibs, 6
sets of 3 sibs, and 1 set of 4 sibs. In the single group there
were 64 single CF patients. Altogether data was analyzed
from 128 patients, 12 to 47 years-of-age. There were no
significant differences between the sibs group and the
singles in anthropometric data, growth indices, airway
bacterial colonization, and CF-related conditions. No dif-
ferences were found in last mean FEV1 and mean number of
hospitalization (67.3  25.1 vs. 70.8  23.3 %predicted and
1.8  2.2 vs. 1.8  1.9 hospitalizations per year, respec-
tively, NS). Number of lung transplantations for the sibs and
the singles was 8 (14%) and 5 (9%), respectively (NS), with
an average age for transplantation of 23.2  9.2 and
31.8  9 years, respectively (NS). The only difference be-
tween the groups was more religious patients in the siblings
compared to the singles (35/64 vs. 15/64, respectively,
p < 0.03).
Subgroup analysis for 21 pairs of 2-sibs with their indi-
vidually matched singles also showed more religious pa-
tients in the 2-sibs compared to the singles (17/42 vs. 7/42,
respectively, p Z 0.0286). Anthropometric data, growth
indices, airway bacterial colonization, and other CF-related
conditions or social parameters were similar. Last mean
FEV1 was 63  30.3 %predicted for 2-sibs and 72.2  22.4 %
predicted for singles (NS), and rate of decline of FEV1 was
also similar (1.3  5.8% vs. 1.2  2% per year, respec-
tively, NS). Mean number of hospitalizations was 2.1  2.2
hospitalizations per year for the 2-sibs and 1.7  2.1 hos-
pitalizations per year for the singles (NS). Number of lung
transplantations for the 2-sibs and the singles was 5 (12%)
and 3 (7%), respectively, (NS) (Table 1).
Subgroup analysis for 7 sets of 3 sibs and 1 set of 4 sibs
with their individually matched singles showed that in the
3/4-sibs group there was more airway colonization by P.
aeruginosa and M. abscessus compared to their matched
Table 2 Comparison between the 3/4-sibs subgroup and
matched singles.
3/4 siblings
(n Z 22)
Singles
(n Z 22)
p value
Age (yr) 23.1  11.5 23.6  10.7 NS
Gender (m/f) 9/13 9/13 NS
Mutation IeIII (y/n) 12/10 12/10 NS
Height (cm) 158  17 160  19 NS
Weight (kg) 50  14 52  16 NS
P. aeruginosa e n (%) 15 (68) 8 (36) Z0.0329
S. aureus e n (%) 8 (36) 9 (41) NS
M. abscessus e n (%) 7 (32) 4 (18) Z0.0332
A. fumigatus e n (%) 8 (36) 6 (27) NS
Associated
diseases e n (%)
17 (77) 19 (86) NS
CFRDM e n (%) 10 (45) 9 (41) NS
PI e n (%) 15 (68) 13 (59) NS
Dios e n (%) 5 (23) 3 (14) NS
FEV1 (%predicted) 58.4  27.5 72.7  25.4 Z0.0495
Rate of decline
of FEV1 (%/y)
5  6.4 1.7  2.8 Z0.0125
Hospitalization (n/yr) 1.7  1.8 0.9  1.2 Z0.0547
Lung
transplantations e
n (%)
5 (23) 2 (9) Z0.0113
Religious
families n (%)
18 (82) 8 (36) Z0.05
BMI e Body Mass index, CFRDM e CF related Diabetes mellitus,
DIOS eDistal intestinal obstruction syndrome, PI e Pancreatic
Insufficiency.
Figure 1 Last mean FEV1 within the family in the 3/4-sibs
subgroup.
Table 1 Comparison between the 2-sibs subgroup and
matched singles.
2-siblings
(n Z 42)
Singles
(n Z 42)
p
value
Age (yrs) 26.1  9.2 25.4  9.4 NS
Gender (m/f) 21/21 21/21 NS
Mutation IeIII (y/n) 34/8 34/8 NS
Height (cm) 165  13 164  12 NS
Weight (kg) 55  15 54  11 NS
P. aeruginosa e n (%) 33 (79) 33 (79) NS
Staphylococcus
aureus e n (%)
15 (36) 18 (43) NS
Mycobacterium
abscessus e n (%)
17 (40) 16 (38) NS
Aspergillus
fumigatus e n (%)
12 (29) 15 (36) NS
Associated
diseases e n (%)
35 (83) 38 (90) NS
CFRDMe n (%) 13 (31) 16 (38) NS
PI e n (%) 28 (67) 35 (83) NS
Dios e n (%) 14 (33) 10 (24) NS
FEV1 (%predicted) 63  30.3 72.2  22.4 NS
Rate of decline
of FEV1 (%/y)
1.3  5.8 1.2  2 NS
Hospitalization (n/yrs) 2.1  2.2 1.7  2.1 NS
Lung
transplantations e
n (%)
5 (12) 3 (7) NS
Religious
families e n (%)
17 (40) 7 (17) Z0.0286
BMI e Body Mass index, CFRDM e CF related Diabetes mellitus,
DIOS eDistal intestinal obstruction syndrome, PI e Pancreatic
Insufficiency.
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respectively, p < .05). FEV1 was significantly lower for the
3/4-sibs subgroup with a faster decline rate compared to
singles (58.4  27.5%predicted vs. 72.7  25.4%predicted
for last mean FEV1 and 5  6.4 vs. 1.7  2.8%predicted
per year, respectively, p < .05). Lung transplantations were
significantly more prevalent in the 3/4-sibs subgroup (5
(23%) vs. 2 (9%), respectively, p < .02) There were more
religious patients in the 3/4-sibs compared to the singles
(18/22 vs. 8/22, respectively, p < .05). A trend toward
more hospitalizations was found in the 3/4-sibs group
(1.7  1.8 vs. 0.9  1.2 hospitalizations per year, respec-
tively, p Z 0.0547) (Table 2).
We further compared FEV1 within siblings and found that
last mean FEV1 was significantly lower for the youngest sib
as shown in Fig. 1 (p < .05).
Discussion
This study compares disease expression and outcome in
families with multiple CF patients compared to families
with only one CF patient. We found that patients from
families with 3 or more siblings with CF show lower FEV1, a
faster decline rate of FEV1, more bacterial airway coloni-
zation, increased frequency of lung transplants, and atrend towards more hospitalizations compared to single CF
patients in a family. However, 2-sibs within one family did
not have such an impact.
The significant determinants of disease progression in CF
may include severe genotype, poor growth, pulmonary ex-
acerbations, meconium ileus, and infection with mucoid P.
aeruginosa [11]. In this study we show that multiple family
members with CF are another risk factor for poor prognosis
as shown by a lower FEV1 with a faster rate of decline of
FEV1 and ultimately by more lung transplants.
Airway colonization with P. aeruginosa has been associ-
ated with a more rapid decline in pulmonary function
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prevalent in the 3/4-sibs. This may be attributed to either
cross-transmission between family members or acquisition
from common environmental exposure. Since families share
the same household it may be assumed that once one of
sibs is infected by an airway pathogen, the other sibs are
likely to also be infected. A prior study of siblings done in
Israel by Picard et al. showed that when Pseudomonas was
isolated from the first-born patient, 91% of the second
siblings were also positive for Pseudomonas colonization
[1]. Moreover, younger siblings tend to be colonized with
Pseudomonas at an earlier age [3]. The cross-infection is
also supported by studies showing that siblings share the
same genotypes of strains of P. aeruginosa [6,16e20]. Apart
from Pseudomonas there are other bacterial pathogens that
are associated with a worse clinical outcome such as M.
abscessus, which was also more prevalent in our group of
patients. As previously shown, M. abscessus is also associ-
ated with a faster lung function decline [21]. Whole
genome sequencing has revealed frequent transmission of
multidrug resistant NTM between patients with cystic
fibrosis attending the same clinic despite conventional
cross-infection measures [22], so it may be expected that
siblings sharing the same household might also cross-infect
each other with the same strain of Mycobacterium.
Furthermore, worse clinical outcome may reflect the
burden of disease in families with several CF patients. The
simultaneous rise in the complexity of the care regimen and
the shift of care to the home means that the burden of care
increasingly falls on patients and families; this requires that
family caregivers provide direct and complex clinical care
that was previously provided by professionals [23]. Such a
shift in care requires not only greater technical skill on the
part of family caregivers, but also a substantial commitment
of time and energy. Parents of children with CF know the
demands of the CF regimen well, and the work of parents as
family caregivers for children with CF is well documented.
Studies that examined the quality of life of parental care-
givers and siblings of children with CF [24e27] and the
relationship between family function and the health of the
child with CF [28,29] showed that there is a negative cor-
relation between the level of burden experienced by par-
ents of children with CF and decreased pulmonary function
over time. Coyne et al. described the time consuming and
complex daily care for children with CF and pointed to the
need to provide support for their parents [26]. The daily
treatment regimen along with the frequent clinic visits and
hospitalizations during pulmonary exacerbation is a lot to
deal with when one child has CF. For parents with 3 or more
sick children it may be assumed that the task is almost
impossible, both technically and emotionally. Collaco et al.
showed that parents caring for 2 children with CF divide
their time and resources in caring for both children, but
once the older sibling has left the home, the remaining
sibling’s pulmonary function is increased, perhaps as a result
of increased resources being devoted to that remaining
sibling [30]. In our study, a trend toward more hospitaliza-
tions was also seen in this group of patients. Frequent hos-
pitalizations impose great burden on the patient’s family,
especially when more than one patient is hospitalized
simultaneously. Hospitalizations also put the CF patient at
risk for airway contamination and acquisition ofPseudomonas and other bacterial pathogens that enhance
disease progression. Moreover, every pulmonary exacerba-
tion enhances lung tissue destruction, which explains the
lower pulmonary function seen in the 3/4-sibs group.
Another important aspect that may contribute to disease
severity is that multiple siblings are found more in religious
families. This finding is expected because although genetic
testing is prevalent in Israel, religious parents tend to
perform less genetic testing or pregnancy termination. In
the current era of prenatal diagnosis and newborn
screening the importance of genetic consultation for fam-
ilies with children with CF is of high importance. Studies
exploring the choice to abort a CF fetus after already caring
for a child with CF showed results ranging from 20% in some
parts of the US [31] to over 50% in France, UK, and Belgium
[32e34]. Several psychosocial factors underline decisions
about use of prenatal diagnosis for CF among parents of
affected children. Wertz et al. demonstrated that the
majority of affected families reject selective abortion for
CF and that many will curtail childbearing rather than use
prenatal diagnosis [9]. Therefore, the choice standing
before religious parents is complex and often controversial.
Furthermore, religious patients may not fully adhere to
treatment and follow up due to their religious beliefs in
divine providence and different apprehension of disease.
Looking into each sibling’s data in the 3/4-sibs group we
found that FEV1 was lower for the youngest sib. Earlier
studies have demonstrated lack of difference in clinical
outcomes between siblings when looking at 2-siblings [2].
Moreover, although younger siblings tend to be colonized
with Pseudomonas at an earlier age, they may show better
lung function outcomes [3]. This may result from the fact
that the second-born sibling is often diagnosed at an earlier
age compared to the first-born due to high index of suspi-
cion [1,3] and this counts as a good prognostic factor
because an early diagnosis of CF is associated with better
lung function after two decades of life [3]. This underscores
the importance of early diagnosis with newborn screening
and early referral to a specialized center in the prevention
of long-term deleterious effects on lung function [3].
However, Munck et al. reported that nearly 9% of families
with an infant screened for CF were unaware of an affected
older sibling [4]. In contrast, our data showed that FEV1
was lower in the youngest sib in the 3/4-sib group, sug-
gesting depletion with time of parental and family re-
sources, and that despite the early diagnosis the enormous
burden of treatments on a family of so many CF patients
may impact the clinical outcome of the youngest patient.
Since such results did not exist in the 2-sibs group it may be
assumed that a crucial limit is crossed when a third sick
child is added to the family.
There are some limitations to our study. The study was
performed retrospectively in one CF center. However, our
center is the national center for CF in Israel and includes
the largest number of patients in Israel and the oldest pa-
tients. Although data was collected retrospectively it
allowed us to follow disease progression for a long period of
time until a relatively old age.
In conclusion, we suggest that 3 or more CF patients in
one family may be a risk factor for more severe disease and
poor prognosis as manifested by lower PFTs, a faster
decline rate of PFTs, more bacterial airway colonization,
78 M. Lavie et al.and increased frequency of lung transplant. This reflects, in
our view, the burden of disease on the patients and fam-
ilies. Medical staff should be aware of this risk factor and
consult infected families accordingly.
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